Loading provider…
Loading provider…
Medical Oncology Physician in New Brunswick, NJ
NPI: 1285997569Primary Practice Location
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL
1 Robert Wood Johnson Pl, New Brunswick, NJ
Primary Employer
Rutgers Health-Rwj Scleroderma Program
rutgershealth.org
HQ Phone
Get Mridula's Phone Numberphone_androidMobile
Get Mridula's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
NJ State Medical License
Rutgers Robert Wood Johnson Medical School
Medical School
Until 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 69 | 106 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 36 | 99 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 27 | 27 |
Authors: Sagar Sardesai, Robert Wesolowski, Mathew Cherian, Dionisia Quiroga, Margaret Gatti-Mays, Preeti Sudheendra, Jasmine Sukumar, Daniel Stover
Journal: Cancer Med
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
Authors: Sadaf Qureshi, Shridarr Ganesan, Deborah Toppmeyer
Journal: Front Oncol
Publication Date: 2021-07-12
The Present and Future of Postmastectomy Radiation.
Authors: Nisha Ohri, Bruce Haffty
Journal: Int J Radiat Oncol Biol Phys
Lead Sponsor: Mridula George, MD
Collaborators: National Cancer Institute (NCI), Incyte Corporation, Oncolytics Biotech
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, BIOLOGICAL: Pelareorep, BIOLOGICAL: Retifanlimab
Lead Sponsor: Oncolytics Biotech
Collaborators: PrECOG, LLC.
Intervention / Treatment: DRUG: Paclitaxel, DRUG: Avelumab, BIOLOGICAL: Pelareorep
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Intervention / Treatment: DRUG: Placebo, DRUG: Trastuzumab, DRUG: Pertuzumab, DRUG: Tucatinib, DRUG: Combination product: Trastuzumab + Pertuzumab